Contents
Volume 93 Issue 12 | JNNP December 2022

Editorial commentary
1237 Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy
S Kawahara, T Saito

Neuromuscular
1239 Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy

1247 Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy
Y A Rekhabally, S Afzal, I K Loo, HS Goede

1253 Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease

Neurogenetics
1269 Clinical and genetic analysis of familial neumyelitis optica spectrum disorder in Chinese: associated with ubiquitin-specific peptidase USP18 gene variants
Y Cheng, L Zhou, X Zheng, Z Shi, X Sun, Y Wang, R Li, Y Long, H Zhou, C Quan, A G Kermode, Q Yu, W Qiu

1276 A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
R H Horton, D Saade, T Markati, E Hamnis, C G Bönnemann, F Muntoni, L Servais

1289 Clinical features of NOTCH2NLC-related neuronal intranuclear inclusion disease
Y Tian, L Zhou, J Gao, B Jiao, S Zhang, Q Xiao, J Xue, Y Wang, H Hang, Y Liu, G Ji, C Mao, C Liu, L Dong, L Zhang, S Zhang, J Yi, G Zhao, Y Luo, Q Sun, Y Zhou, F Yi, X Chen, C Zhou, N Xue, M Luo, L Yao, Y Hu, M Zhang, Q Zeng, L Fang, H-Y Long, Y Xie, L Weng, S Chen, J Du, Q Xu, L Feng, Q Huang, X Hou, J Wang, B Xie, I Zhou, L Long, J Gao, J Wang, X Yan, H Jiang, H Xu, R Duan, B Tang, L Shen

Epilepsy
1299 Efficacy of pulse intravenous methylprednisolone in epileptic encephalopathy: a randomised controlled trial

Neurodegeneration
1262 Neurodegenerative disease risk among former international rugby union players
E R Russell, D F Mackay, D Lyall, K Stewart, J A MacLean, J Robson, J P Pell, W Stewart

Disclosures: The Editor of JNNP has been granted editorial freedom and JNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNP is primarily intended for healthcare professionals and its content is for information only. The journal is published without any guarantee as to its accuracy or completeness and any representation or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage however arising from JNP except for liability which cannot be legally excluded.

Copyright: © 2022 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission.

JNP is published by BMJ Publishing Group Ltd, typeset by Exerter Premedia Services Private Ltd, Chennai, and printed in the UK on acid-free paper from sustainable forests.

Journal of Neurology, Neurosurgery & Psychiatry
ISSN 0022-3050 (UPSP 2156) is published monthly by BMJ Publishing Group Ltd, BMJ House, Tavistock Square, WC1H 9JR London. Artwork and mailing in the USA by agent named World Container Inc., 150-15, 18th Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Journal of Neurology, Neurosurgery & Psychiatry, World Container Inc., 150-15, 18th Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMJ House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.
Multiple sclerosis

1306 Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis


1317 Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark

E Frantise, I Pontieri, S Bramow, F Selabjerg, M Magrass

1322 Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry


1330 Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis


Movement disorders

1338 Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson’s disease?

S S Xu, W-L Lee, T Perez, N C Sinclair, K J Bullas, H J McDermott, W Thevarasah

Neuro-inflammation

1343 Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations

D Plantone, S Locci, L Bregantini, C Manco, R Cortese, M Mercoli, D Cavallaro, M d’Alessandro, E Barbagli, N De Stefano

Electronic page
e3 The British Neuropsychiatry annual meeting abstracts